Zimmer Biomet Holdings Inc.
ZBH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ZBH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ZBH
Zimmer Biomet Holdings Inc. is a global medical technology company that designs, manufactures, and markets musculoskeletal healthcare products and solutions, with a focus on orthopedic implants, surgical instruments, and digital health technologies.
Key risk: Regulatory compliance burden
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$19.25B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 91 clinical trials for Zimmer Biomet Holdings Inc..
Zimmer Biomet Holdings Inc. is a global medical technology company that designs, manufactures, and markets musculoskeletal healthcare products and solutions, with a focus on orthopedic implants, surgical instruments, and digital health technologies.
- As of 2026-06-30, Zimmer Biomet reported cash & equivalents of $410.0M, total revenue of $2,177.0M, net income of $198.3M, shareholders' equity of $12,697.7M, and total debt of $7,479.0M [sec].
- Consolidated net sales were $8,231 million in 2025, up from $7,679 million in 2024 and $7,394 million in 2023 [sec · filed 2026-04-01].
- The company faces ongoing regulatory and compliance challenges, including FDA inspectional observations and healthcare fraud/abuse laws [sec_mda · as of 2026-08-05].
- Zimmer Biomet has a capital commitment of up to $300 million to an investment fund focusing on musculoskeletal and rheumatologic innovations, callable over four years [sec_mda · as of 2026-05-01].
- The company expects foreign currency to have a 0.5% positive impact on year-over-year net sales growth based on exchange rates at the end of 2025 [sec_mda · as of 2026-08-05].
What works
- Revenue growth trajectory: Consolidated net sales increased from $6,940 million in 2022 to $8,231 million in 2025, indicating consistent top-line expansion [sec · filed 2026-04-01].
- Operational leverage expected: Management projects operating profit to increase in 2026 due to higher net sales, fixed expense leverage, and ongoing restructuring savings [sec_mda · as of 2026-08-05].
- Strategic investment in innovation: The company committed up to $300 million to an investment fund targeting transformative musculoskeletal and rheumatologic healthcare innovations [sec_mda · as of 2026-05-01].
What to weigh
- High debt load: Total debt of $7,479.0M against shareholders' equity of $12,697.7M as of 2026-06-30, representing significant leverage [sec].
- Regulatory and compliance risks: The company must remediate FDA inspectional observations and comply with complex healthcare regulations, which could disrupt operations [sec_mda · as of 2026-08-05].
- Contingent payment obligations: Future payments under development and distribution arrangements could range from $0 to approximately $525 million, creating financial uncertainty [sec_mda · as of 2026-05-01].
- Dependence on new product development and innovation: The company faces risks from technological obsolescence and changing customer demand [sec_mda · as of 2026-05-01].
From the filings
Quoted directly from source documents.
Revenue growth from 2022 to 2025
“Consolidated Net Sales | 2025 | | | 2024 | | | 2023 | | | 2022 | | | 2021(1) | | | | | | | | As Reported | $ | 8,231 | | | $ | 7,679 | | | $ | 7,394 | | | $ | 6,940 | | | $ | 7,836”
SEC filings · April 1, 2026
Capital commitment to investment fund
“we executed in the three-month period ended March 31, 2026, to invest in an investment fund with a capital commitment of up to $300 million, which is expected to become callable over a four year period.”
SEC MD&A · May 1, 2026
Expected positive FX impact on net sales
“Based on foreign currency exchange rates at the end of 2025, we expect foreign currency to have a 0.5 percent positive impact on year-over-year net sales growth.”
SEC MD&A · August 5, 2026
Contingent payment range
“These estimated payments could range from $0 to approximately $525 million.”
SEC MD&A · May 1, 2026
Risks & what to watch (4)›
Key risks
- Regulatory compliance burden — Challenges from FDA inspectional observations and healthcare fraud/abuse laws may disrupt operations [sec_mda · as of 2026-08-05].
- High leverage and debt — Total debt of $7,479.0M as of 2026-06-30 increases financial risk and interest expense [sec].
- Contingent payment uncertainty — Future payments under development/distribution deals could reach $525M, impacting cash flow [sec_mda · as of 2026-05-01].
- Dependence on innovation — Reliance on new product development and technological advances exposes the company to obsolescence risk [sec_mda · as of 2026-05-01].
What to watch
- Progress on remediating FDA inspectional observations and their impact on product supply [sec_mda · as of 2026-08-05].
- Execution of the $300 million investment fund commitment and its effect on innovation pipeline [sec_mda · as of 2026-05-01].
- Trend in net sales growth and operating profit in 2026, particularly the impact of foreign exchange and restructuring savings [sec_mda · as of 2026-08-05].
- Resolution of contingent payment obligations and their potential cash flow implications [sec_mda · as of 2026-05-01].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Zimmer Biomet Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Zimmer Biomet Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.81 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 3 sells (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
912
Total value held
$16.31B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 25,586,824 | $2.31B |
| dodge & cox | 23,542,700 | $2.13B |
| blackrock, inc. | 15,340,806 | $1.39B |
| harris associates l p | 12,959,939 | $1.17B |
| state street corp | 8,825,127 | $800.1M |
| vanguard portfolio management llc | 8,650,228 | $782.2M |
| franklin resources inc | 5,452,665 | $493.0M |
| geode capital management, llc | 5,379,525 | $484.6M |
| american century companies inc | 3,963,206 | $358.4M |
| primecap management co/ca/ | 3,907,150 | $353.3M |
Showing top 10 of 912 institutional holders of Zimmer Biomet Holdings Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 15, 2026- % of float
- 6.8%
- Days to cover
- 4.0
- Shares short
- 9,996,758
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ZBH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Zimmer Biomet Holdings Inc.?
Zimmer Biomet Holdings Inc. is a global medical technology company that designs, manufactures, and markets musculoskeletal healthcare products and solutions, with a focus on orthopedic implants, surgical instruments, and digital health technologies.
Who is the CEO of Zimmer Biomet Holdings Inc.?
Mr. Ivan Tornos is the chief executive officer of Zimmer Biomet Holdings Inc. (ZBH).
Where is Zimmer Biomet Holdings Inc. headquartered?
Zimmer Biomet Holdings Inc. (ZBH) is headquartered in Warsaw, IN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.